CN113038939A - 损害内施用pd-1抑制剂用于治疗皮肤癌 - Google Patents

损害内施用pd-1抑制剂用于治疗皮肤癌 Download PDF

Info

Publication number
CN113038939A
CN113038939A CN201980074748.7A CN201980074748A CN113038939A CN 113038939 A CN113038939 A CN 113038939A CN 201980074748 A CN201980074748 A CN 201980074748A CN 113038939 A CN113038939 A CN 113038939A
Authority
CN
China
Prior art keywords
inhibitor
tumor
amino acid
seq
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980074748.7A
Other languages
English (en)
Chinese (zh)
Inventor
M·G·菲里
I·洛伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN113038939A publication Critical patent/CN113038939A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
CN201980074748.7A 2018-11-14 2019-11-13 损害内施用pd-1抑制剂用于治疗皮肤癌 Pending CN113038939A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862767218P 2018-11-14 2018-11-14
US62/767,218 2018-11-14
PCT/US2019/061212 WO2020102375A1 (en) 2018-11-14 2019-11-13 Intralesional administration of pd-1 inhibitors for treating skin cancer

Publications (1)

Publication Number Publication Date
CN113038939A true CN113038939A (zh) 2021-06-25

Family

ID=68841191

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980074748.7A Pending CN113038939A (zh) 2018-11-14 2019-11-13 损害内施用pd-1抑制剂用于治疗皮肤癌

Country Status (16)

Country Link
US (2) US12473364B2 (https=)
EP (2) EP4382168A3 (https=)
JP (2) JP7513604B2 (https=)
CN (1) CN113038939A (https=)
DK (1) DK3880186T3 (https=)
ES (1) ES2980363T3 (https=)
FI (1) FI3880186T3 (https=)
HR (1) HRP20240825T1 (https=)
HU (1) HUE067601T2 (https=)
LT (1) LT3880186T (https=)
PL (1) PL3880186T3 (https=)
PT (1) PT3880186T (https=)
RS (1) RS65627B1 (https=)
SI (1) SI3880186T1 (https=)
SM (1) SMT202400252T1 (https=)
WO (1) WO2020102375A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
LT3394103T (lt) 2015-12-22 2023-09-11 Regeneron Pharmaceuticals, Inc. Antikūnų prieš pd-1 ir bispecifinių antikūnų prieš cd20/cd3 derinys, skirtas vėžiui gydyti
EP4313123A1 (en) * 2021-03-23 2024-02-07 Regeneron Pharmaceuticals, Inc. Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL354286A1 (en) 1999-08-23 2003-12-29 Dana-Farber Cancer Institutedana-Farber Cancer Institute Pd-1, a receptor for b7-4, and uses therefor
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
EP2195342A1 (en) 2007-09-07 2010-06-16 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
CA2840018C (en) 2011-07-24 2019-07-16 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
EP2825036B1 (en) 2012-03-16 2018-05-02 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
KR20220084444A (ko) 2012-05-31 2022-06-21 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
RU2689760C2 (ru) 2012-05-31 2019-05-30 Дженентек, Инк. Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
US10092645B2 (en) 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
KR102476226B1 (ko) 2014-08-05 2022-12-12 아폴로믹스 인코포레이티드 항-pd-l1 항체
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
JP6295998B2 (ja) 2015-05-12 2018-03-20 株式会社デンソー 内燃機関の再始動制御装置
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
AU2016317915B2 (en) 2015-09-01 2021-02-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
ES2986067T3 (es) 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
LT3394103T (lt) 2015-12-22 2023-09-11 Regeneron Pharmaceuticals, Inc. Antikūnų prieš pd-1 ir bispecifinių antikūnų prieš cd20/cd3 derinys, skirtas vėžiui gydyti
KR20180108655A (ko) 2016-01-15 2018-10-04 알에프이엠비 홀딩스, 엘엘씨 암의 면역학적 치료
SG11201808626WA (en) 2016-04-07 2018-10-30 Chemocentryx Inc Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
TWI910495B (zh) 2016-05-13 2026-01-01 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
DK3551660T5 (da) 2016-12-07 2024-09-02 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
MA47604A (fr) 2017-02-21 2020-01-01 Regeneron Pharma Anticorps anti-pd-1 pour le traitement du cancer du poumon
US10166290B2 (en) 2017-02-24 2019-01-01 Max H. Cohen Intralesional (Intratumoral) dinitrochlorobenzene and associated compounds coadministered with checkpoint inhibitors for cancer treatment including treatment of metastatic cutaneous cancers
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
CN111201035A (zh) 2017-06-19 2020-05-26 梅迪塞纳医疗股份有限公司 Il-2超激动剂、激动剂及其融合体的用途和方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GERALD S. FALCHOOK 等: "Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810", 《JOURNAL FOR IMMUNOTHERAPY OF CANCER 》, vol. 4, no. 70, pages 1 - 5, XP021241444, DOI: 10.1186/s40425-016-0176-3 *
KYRIAKOS P PAPADOPOULOS 等: "Cemiplimab (REGN2810) : A fully human anti-PD-1 monoclonal antibody for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma(CSCC)—Initial safety and efficacy from expansion cohorts (ECs) of phase I study", 《JOURNAL OF CLINICAL》, vol. 36, no. 5, pages 1 - 4 *
M.R. MIGDEN 等: "PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma", 《THE NEW ENGLAND JOURNAL O F MEDICINE》, vol. 379, no. 4, pages 341 - 351, XP055694330, DOI: 10.1056/NEJMoa1805131 *

Also Published As

Publication number Publication date
HUE067601T2 (hu) 2024-10-28
US12473364B2 (en) 2025-11-18
EP4382168A3 (en) 2024-08-28
US20260042841A1 (en) 2026-02-12
FI3880186T3 (fi) 2024-05-30
JP7513604B2 (ja) 2024-07-09
RS65627B1 (sr) 2024-07-31
PL3880186T3 (pl) 2024-07-22
HRP20240825T1 (hr) 2024-09-27
ES2980363T3 (es) 2024-10-01
EP4382168A2 (en) 2024-06-12
WO2020102375A1 (en) 2020-05-22
SMT202400252T1 (it) 2024-07-09
JP2022513029A (ja) 2022-02-07
EP3880186B1 (en) 2024-04-03
US20210388091A1 (en) 2021-12-16
SI3880186T1 (sl) 2024-07-31
LT3880186T (lt) 2024-06-10
PT3880186T (pt) 2024-05-28
DK3880186T3 (da) 2024-06-03
JP2024123216A (ja) 2024-09-10
EP3880186A1 (en) 2021-09-22

Similar Documents

Publication Publication Date Title
KR102595561B1 (ko) Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법
JP2022532490A (ja) 癌の治療における有効性の増強のためのｐｄ－１阻害剤とｌａｇ－３阻害剤の組み合わせ
US20260042841A1 (en) Intralesional administration of pd-1 inhibitors for treating skin cancer
AU2020228296B2 (en) Administration of PD-1 inhibitors for treating skin cancer
JP2025041768A5 (https=)
CN121127264A (zh) 用于在治疗黑素瘤中增强疗效的pd-1抑制剂和lag-3抑制剂组合
HK40112560A (en) Intralesional administration of pd-1 inhibitors for treating skin cancer
HK40057287A (en) Intralesional administration of pd-1 inhibitors for treating skin cancer
HK40057287B (en) Intralesional administration of pd-1 inhibitors for treating skin cancer
RU2842292C1 (ru) Способы лечения рака посредством введения ингибитора pd-1
RU2771759C2 (ru) Антитела против pd-1 для лечения рака легких
HK40002353A (en) Methods of treating skin cancer by administering a pd-1 inhibitor
HK40002353B (en) Methods of treating skin cancer by administering a pd-1 inhibitor
EA049388B1 (ru) Способы лечения базально-клеточной карциномы путем введения антитела или его антигенсвязывающего фрагмента, специфически связывающихся с pd-1

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination